Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active surveillance and carboplatin versus cisplatin in pediatric and adult germ cell tumors
2018-004141-17Phase 3Unknown
- Sponsor
- Children's Oncology Group
- Start
- Jul 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and cisplatin in germ cell tumor (GCT), Germ cell ovarian tumor, Germ Cell Testicular Cancer and 1 more (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Overall survival in low-risk stage I ovarian immature teratoma grade 2 or 3 and Incidence of ototoxicity. Status: unknown.
02
Drugs
carboplatincisplatin
03
Conditions
germ cell tumor (GCT)Germ cell ovarian tumorGerm Cell Testicular Cancerextragonadal germ cell tumor (EGGCT)
Beyond the preview
Go deeper on 2018-004141-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004141-17.